CYTKCytokinetics, Incorporated
$61.22+3.8% 1Y
$61.22
$54.7652 weeks$87.24
Is the business good?
Good
1 good, 3 without dataMargins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margin direction, 3 years+4096.4 ptsderived
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is CYTK?
Cytokinetics, Incorporated spent more than it took in: an operating loss of $708M on $68M of revenue, 12 months to Q2 2026.
$708M
Operating loss · on $68M of revenue · 12 months to Q2 2026
| Year | Operating margin |
|---|---|
| FY2020 | −168% |
| FY2021 | −265% |
| FY2022 | −343% |
| FY2023 | −6590% |
| FY2024 | −2903% |
| FY2025 | −695% |
Details›
- Operating margin12 months to Q2 2026
- −1046%
- Net margin12 months to Q2 2026
- −1321%
- Free cash flow margin
- −858%
- R&D as % of revenue
- 587%
- Revenue, trailing twelve months
- $68M
- Free cash flow, trailing twelve months
- −$581M
- Net income, trailing twelve months
- −$894M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
On our screens:Most shorted stocks